BofA analyst Travis Steed upgraded Edwards Lifesciences (EW) to Buy from Neutral with a price target of $90, up from $82. The path in 2025 “skews higher” given several potential catalysts and strategic value in TAVR, the analyst tells investors. Earnings have been reset for spin/deal dilution and can grow double digits, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $83 from $81 at Citi
- Early notable gainers among liquid option names on December 10th
- Class Action Lawsuit Against Edwards Lifesciences Corp. (NYSE:EW)
- Edwards Lifesciences price target raised to $75 from $70 at Stifel
- Edwards Lifesciences price target raised to $78 from $70 at Truist
Questions or Comments about the article? Write to editor@tipranks.com